A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation  by Sharafkhaneh, Amir et al.
Respiratory Medicine (2014) 108, 1310e1320Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier .com/locate /rmedA simple rule to identify patients with
chronic obstructive pulmonary disease who
may need treatment reevaluation
Amir Sharafkhaneh a,*, Aylin E. Altan b,1, Gene L. Colice c,
Nicola A. Hanania d, James F. Donohue e,
Jonathan L. Kurlander b, Roberto Rodriguez-Roisin f,
Pablo R. Altman g,2a Pulmonary and Critical Care, Baylor College of Medicine, MEDVA Medical Center Bldg. 100 (111i),
Houston, TX 77030, USA
b Health Economics and Outcomes Research, OptumInsight, 13625 Technology Drive, Eden Prairie,
MN 55344, USA
c Pulmonary, Critical Care and Respiratory Services, Washington Hospital Center, 110 Irving Street,
Washington DC, 20010, USA
d Pulmonary and Critical Care, Baylor College of Medicine, One Baylor Plaza-BCM621, Houston,
TX 77030, USA
e Pulmonary Diseases and Critical Care Medicine, University of North Carolina School of Medicine,
4125 BioInformatics Building, 130 Mason Farm Road, CB 7020, Chapel Hill, NC 27599, USA
f Thorax Institute, Hospital Clinic-CIBERES, IDIBAPS, Universitat de Barcelona, Villarroel,
170 (Esc 2 e Planta 2), 08036 Barcelona, Spain
g Mylan Specialty, L.P., 110 Allen Road, 4th Floor, Basking Ridge, NJ 07920, USAReceived 18 February 2014; accepted 4 July 2014
Available online 14 July 2014Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic
Obstructive Lung Disease; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; ICS, inhaled cortico-
steroid; IMPACT, Impact National Benchmark Database; IV, intravenous; LABA, long-acting inhaled b2-agonist; LAMA, long-acting inhaled
muscarinic antagonist; MDI, metered-dose inhaler; MPR, medication possession ratio; ORD, Optum Research Database; PPY, per patient
year; SABA, short-acting inhaled b2-agonist; SAMA, short-acting inhaled muscarinic antagonist; SD, standard deviation.
* Corresponding author. Tel.: þ1 713 794 7668; fax: þ1 713 794 7295.
E-mail addresses: amirs@bcm.edu (A.Sharafkhaneh), Aylin.Altan@optum.com (A.E.Altan), Gene.Colice@Medstar.net (G.L.Colice),
hanania@bcm.tmc.edu (N.A.Hanania), james_donohue@med.unc.edu (J.F.Donohue), Jonathan.Kurlander@optum.com (J.L.Kurlander),
rororo@clinic.ub.es (R.Rodriguez-Roisin), Pablo.Altman@gmail.com (P.R.Altman).
1 Previously published under Aylin A. Riedel.
2 Employed by Mylan Specialty, L.P., at the time of data analysis.
http://dx.doi.org/10.1016/j.rmed.2014.07.002
0954-6111/ª 2014 Published by Elsevier Ltd.
Rule of 3e2 for COPD 1311KEYWORDS
COPD;
Exacerbation;
SABA;
Maintenance therapySummary
Background: A simple rule based on short-acting inhaled b2-agonist (SABA) use could identify
patients with chronic obstructive pulmonary disease (COPD) at increased risk of exacerbations
and signal the need for maintenance therapy change, similar to asthma “Rules of Two”.
Methods: Associations between SABA use, COPD exacerbations, and health care costs over 1
year were examined retrospectively using de-identified patient data from the Optum Research
Database (ORD; N Z 56,581) and the Impact National Benchmark Database (IMPACT;
N Z 9423). Nebulized and metered-dose inhaler (MDI) SABA doses were normalized to
2.5 mg and 90 mcg albuterol equivalents, respectively.
Results: The GOLD initiative establishes 2 exacerbations/year as indicative of increased risk
in COPD. We identified a correlation (p < 0.0001) between 1.5 SABA doses/day and this fre-
quency of exacerbations. In ORD, patients using 1.5 versus <1.5 SABA doses/day experienced
significantly more exacerbations: 1.92 (95% confidence interval [CI], 1.89e1.96) versus 1.36
(95% CI, 1.34e1.38) per patient year (PPY). Above-threshold use was associated with higher
average annual COPD-related costs (2010 $US): $21,868 (standard deviation [SD], $53,910)
versus $11,686 (SD, $32,707) for nebulized SABA only, $9216 (SD, $30,710) versus $7334 (SD,
$24,853) for MDI SABA only, and $15,806 (SD, $35,260) versus $11,233 (SD, $27,006) for both
nebulized and MDI SABA. IMPACT validated these findings.
Conclusion: Patients with COPD using 1.5 SABA doses/day were at increased risk of exacer-
bations. Our results suggest a “Rule of 3e2”: SABA use 3 times in 2 days should be considered
a clinical marker for needing treatment reevaluation.
ª 2014 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth
leading cause of death worldwide [1] and the third leading
cause of death in the United States [2]. Its prevalence is
expected to increase dramatically in many countries
with the aging of individuals born between 1946 and 1964
(colloquially, the “baby boomer” generation). The risk of
developing COPD by age 80 is estimated to be about
28% [3].
Most cases of COPD are diagnosed clinically; a recent
study in developed countries found that only 32% of pa-
tients undergo an objective evaluation that includes
spirometry [4]. In the absence of spirometry, the American
College of Physicians recommends using age, smoking his-
tory, and presence of wheezing to diagnose COPD [5]. After
diagnosis, follow-up usually relies on clinical signs and
symptoms without spirometry or validated questionnaires
to inform treatment decisions [6].
COPD exacerbations can reduce quality of life, accel-
erate loss of lung function, and lead to hospitalization or
death if not promptly managed [7e10]. Furthermore,
treatment of exacerbations contributes significantly to the
overall health care cost associated with COPD [11]. The
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) advises using history of exacerbations as an indi-
cator of future risk of exacerbations [9]. A reduced forced
expiratory volume in 1 s (FEV1) has been associated with an
increased risk of exacerbations [12], but few patients un-
dergo spirometry [4].
We sought to develop a much-needed, easy-to-use
clinical marker to identify patients with COPD at increased
risk of exacerbations (similar to the “Rules of Two” [13] inasthma). We hypothesized that increased frequency of
short-acting inhaled b2-agonist (SABA) use could be associ-
ated with increased risk of exacerbations and, therefore,
serve as a signal for reevaluation of maintenance therapy.
Methods
Study design
We performed a retrospective, administrative
claimsebased analysis based on two US databases: the
Optum Research Database (ORD) and the Impact National
Benchmark Database (IMPACT), which contain data from
commercial and Medicare Advantage enrollees [14,15]. All
records were de-identified, and no identifiable protected
health information was extracted or accessed during the
study, pursuant to the United States Health Insurance
Portability and Accountability Act [16]. ORD was used to
develop a rule based on SABA use to identify patients with
COPD at increased risk of exacerbations, and IMPACT was
used to validate findings.
Study patients
Patients with the following criteria were included in the
analysis: at least one medical claim with COPD diagnosis
(International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] 491.xx, 492.x, 496) from
January 1, 2008 through March 31, 2010; a second claim
with COPD diagnosis at least 1 day following the first COPD
diagnosis and within a 1-year period (date of second COPD
diagnosis Z Index Date); age  40 years at Index Date;
1312 A. Sharafkhaneh et al.continuous enrollment for 6 months (182 days) before Index
Date (baseline period); continuous enrollment for at least 1
year (365 days) after and including Index Date (follow-up
period) unless there was earlier evidence of death; and at
least one pharmacy or medical claim indicating use of SABA
during the 1-year follow-up period.
Patients were excluded if they died before the Index
Date or had evidence of inpatient hospitalization within the
90 days before the Index Date or a prescription fill for
nebulized long-acting inhaled b2-agonist (LABA) during the
baseline or follow-up periods.
Use of metered-dose inhaler (MDI) and nebulized
SABA
Daily use of SABA (isoetharine, levalbuterol, albuterol
[including albuterol/ipratropium], bitolterol, isoproter-
enol, pirbuterol, terbutaline, and metaproterenol) was
measured over 1 year, starting with the Index Date. One
dose of MDI SABA was defined as 2 puffs (1 puff Z 90 mcg
albuterol equivalent); 1 dose of nebulized SABA was defined
as 1 nebulization using 1 vial (2.5 mg albuterol equivalent).
SABA quantities prescribed over the period of analysis were5,116,151 Medicare and commercial insurance enrollees with
 medical and pharmacy benefits during the identification period
Exclude those without a claim
for COPD
550,230 patients
Exclude those without a second 
claim for COPD within year
331,599 patients
Exclude if <40 years of age
320,548 patients
Exclude those without baseline and
follow-up continuous enrollment
172,278 patients
Exclude those without at least one
claim for SABA during the 
assessment period
75,818 patients
Exclude patients if inpatient
hospitalization within 90 days of
the index date
57,806 patients
Exclude patients with Rx fill for
nebulized LABA in baseline or
follow-up
56,667 patients
Exclude those with unreconciled
costs in claims
56,581 patients
a
Figure 1 a: Sample attrition for the Optum Research Database
Database (IMPACT). COPD Z chronic obstructive pulmonary disea
SABA Z short-acting inhaled b2-agonist.converted to puffs or vials, based on packaging informa-
tion. For MDI SABA, number of puffs was divided by number
of days to obtain puffs per day, which was divided by 2 to
determine doses per day. For nebulized SABA, number of
vials was divided by number of days to obtain vials per day,
same as doses per day.Outcomes
The primary outcome for the 1-year follow-up period was
COPD exacerbations. These were identified by an ICD-9-CM
code for an exacerbation (ICD-9-CM 491.21 and 492.22); a
COPD-related hospitalization, emergency department visit,
or urgent care visit; a new prescription for an oral corti-
costeroid or administration of an injectable/intravenous
(IV) corticosteroid within 7 days following a COPD-related
ambulatory visit; or a new prescription for an oral antibiotic
or administration of an injectable/IV antibiotic within 7
days following a COPD-related ambulatory visit. Each
“episode” may have consisted of multiple health care en-
counters (exacerbation events) and was considered com-
plete after 7 days without any exacerbation events.390,023 Medicare and commercial insurance enrollees with
 medical and pharmacy benefits during the identification period
Exclude those without a claim
for COPD
192,123 patients
Exclude those without a second 
claim for COPD within year
95,367 patients
Exclude if <40 years of age
89,963 patients
Exclude those without baseline and
follow-up continuous enrollment
31,254 patients
Exclude those without at least one
claim for SABA during the 
assessment period
12,003 patients
Exclude patients if inpatient
hospitalization within 90 days of
the index date
9504 patients
Exclude patients with Rx fill for
nebulized LABA in baseline or
follow-up
9423 patients
Exclude those with unreconciled
costs in claims
9423 patients
b
(ORD). b: Sample attrition for the Impact National Benchmark
se; LABA Z long-acting inhaled b2-agonist; Rx Z prescription;
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costs, computed as combined health plan and patient paid
amounts in the 1-year follow-up period. Costs were
adjusted using the annual medical care component of the
Consumer Price Index to reflect inflation between 2007 and
2010 [17]. Outcomes (exacerbations per patient year [PPY],
rounded to an integer, and COPD-related costs per year)
accounted for variable follow-up times caused by death.
Covariates
Comorbidity burden was determined using the Quan-
Charlson comorbidity score, based on diagnosis codes in
the baseline period [18]. COPD medications used during
baseline and follow-up periods were captured at the class
level (eg, nonnebulized LABA, short-acting inhaled musca-
rinic antagonists [SAMA], SAMA/SABA, long-acting inhaled
muscarinic antagonists [LAMA], inhaled corticosteroids
[ICS], and fixed combination inhaler therapies of LABA/ICS)
and included administrations and pharmacy fills.
Descriptive analysis
To develop a claims-based marker for overuse of SABA, the
relationship between SABA measures and outcomes during
the analysis period was examined using descriptive statis-
tics and plots of SABA use by exacerbations PPY. After a
level of SABA use signaling high risk had been selected,
exacerbations (2 versus <2 based on GOLD initiative
classification of high risk) and COPD-related costs per year
for those above and below the marker level were
examined.
Sensitivity analysis
Four sensitivity analyses were conducted. First, specificity
and sensitivity were examined among subgroups of patientsTable 1 Patient demographics and clinical characteristics
by data source.
Data source
ORD
(N Z 56,581)
IMPACT
(N Z 9423)
Mean (SD) age, years 67.8 (11.3) 62.2 (9.9)
Gender
Male, n (%) 25,050 (44.3) 4271 (45.3)
Insurance type
Commercial, n (%) 29,487 (52.1) 7301 (77.5)
Medicare Advantage, n (%) 27,094 (47.9) 2122 (22.5)
Quan-Charlson comorbidity
index, mean (SD)
2.02 (1.60) 1.58 (1.39)
Select AHRQ comorbid conditions
Asthma, n (%) 12,103 (21.4) 2144 (22.8)
Other lower respiratory
disease, n (%)
27,660 (48.9) 4415 (46.8)
Respiratory infections, n (%) 20,237 (35.8) 3192 (33.9)
AHRQ Z Agency for Healthcare Research and Quality;
IMPACT Z Impact National Benchmark Database;
ORD Z Optum Research Database; SD, standard deviation.within age category, sex, insurance type (commercial or
Medicare), and levels of compliance with various classes of
concomitant COPD medications (measured by medication
possession ratio [MPR]). The purpose of this analysis was to
determine if the marker performed similarly among
different types of patients (and could therefore be applied
generally across the study population). Second, SABA use
was investigated across 90- and 180-day periods to deter-
mine if the length of time over which SABA use was assessed
altered findings. Third, multivariate analysis accounting for
patient factors was performed to assess potential con-
founding. A negative binomial model including quartile of
SABA use (vials or inhalations per day) as the primary pre-
dictor and COPD exacerbations per year as the outcome,
adjusted for baseline covariates and patient characteris-
tics, was created. Generalized linear modeling (GLM) with a
gamma distribution and a log link modeled COPD-related
costs. Finally, findings were validated with IMPACT, a
second and separate data set.
Results
Population characteristics
The total number of available commercial and Medicare
Advantage enrollee records containing medical and phar-
macy benefit claim data was >5.5 million across the two
database populations. Development and validation pop-
ulations consisted of 56,581 and 9423 patients with COPD in
ORD and IMPACT, respectively (Fig. 1a and b).
Although there were significant (p < 0.05) differences
between the ORD and IMPACT patients in age, insurance
coverage, and overall and respiratory comorbidities, these
differences were based on the large sample sizes and not
felt to be clinically meaningful (Table 1). Approximately
one-fifth of patients in each group had diagnosed asthma.
During the 6-month baseline period, most patients (60.3%
ORD, 55.6% IMPACT) used SABA rescue therapy
(Supplemental Table 1). Fewer received SAMA monotherapy
(24.3% ORD, 20.1% IMPACT). About a third of patients in
each database received systemic corticosteroids (35.9%
ORD, 32.0% IMPACT). In the baseline period, the two most
commonly used maintenance therapies were LAMA (18.4%
ORD, 17.5% IMPACT) and ICS/LABA (24.8% ORD, 27.3%
IMPACT). ICS monotherapy, nonnebulized LABA, and
methylxanthine were used less often.
During the 1-year follow-up, over one-half of patients
from ORD (54.4%) and IMPACT (69.8%) used rescue SABA
only with an MDI; 22.0% from ORD and 11.5% from IMPACT
used SABA only by nebulization (Fig. 2a and b). The
remaining patients used both. Systemic corticosteroid use
was common (Table 2). The MPR for the two most
commonly used maintenance medications, ICS/LABA and
LAMA, ranged from 0.39 to 0.64 for the various subgroups
examined. However, in general, less than one-third of pa-
tients using ICS/LABA and LAMA had an MPR 0.80.
Determination of the clinical marker
A positive linear relationship (p < 0.0001) was observed
between the number of SABA doses/day and the incidence
Nebulized 
SABA only:
12,454
PaƟents
(22%)
Both:
13,335
PaƟents
(24%)
ORD: 56,581 paƟents
25,789 PaƟents (46%)
44,127 PaƟents (78%)
<1.5 Doses/day 
18,523 PaƟents 
(72%)
≥1.5 Doses/day 
7266 PaƟents 
(28%)
MDI
SABA only:
30,792
PaƟents
(54%)
<1.5 Doses/day 
29,565 PaƟents
(67%)
≥1.5 Doses/day 
14,562 PaƟents
(33%)
Rescue 
treatment
Nebulized 
SABA only:
1088
PaƟents
(12%)
Both:
1756
PaƟents
(19%)
IMPACT™: 9423 paƟents 
2844 PaƟents (30%)
8335 PaƟents (88%)
<1.5 Doses/day 
2201 PaƟents
(77%)
≥1.5 Doses/day 
643 PaƟents
(23%)
MDI
SABA only:
6579
PaƟents
(70%)
<1.5 Doses/day 
6243 PaƟents
(75%)
≥1.5 Doses/day 
2092 PaƟents
(25%)
Rescue 
treatment
a b
Figure 2 a: SABA use in ORD. b: SABA use in IMPACT. IMPACT Z Impact National Benchmark Database; MDI Z metered-dose
inhaler; ORD Z Optum Research Database; SABA Z short-acting inhaled b2-agonist.
1314 A. Sharafkhaneh et al.of exacerbations (Fig. 3) in ORD. A similar relationship was
observed with IMPACT. The GOLD initiative establishes 2
exacerbations per year (ie, frequent exacerbations) as
indicative of increased risk in COPD [19]. In ORD, this fre-
quency of exacerbations was correlated with 1.5 SABA
doses/day. Data from IMPACT supported this threshold.
This level of SABA use (1.5 SABA doses/day) was consid-
ered the clinical marker of high risk (Fig. 4). Patients using
1.5 SABA doses/day were significantly more likely to have
2 exacerbations during the year analyzed and to have
significantly more days with exacerbation and exacerba-
tions PPY in ORD (Supplemental Table 2). Similar trends
were observed in IMPACT.
In ORD, patients using more than the threshold of 1.5
SABA doses/day were significantly more likely to be
receiving maintenance medications (Table 2). They had
significantly higher annual COPD-related health care
costs (2010 $US): $21,868 (standard deviation [SD],
$53,910) versus $11,686 (SD, $32,707) for nebulized SABA
only, $9216 (SD, $30,710) versus $7334 (SD, $24,853) for
MDI SABA only, and $15,806 (SD, $35,260) versus $11,233
(SD, $27,006) for both nebulized and MDI SABA (Table 3).
Results from IMPACT confirmed these findings. When
costs were analyzed by site of care (inpatient, emergency
department, outpatient, office visit, other medical, and
pharmaceutical), ORD data indicated that 1.5 nebulized
SABA doses/day significantly increased costs at all sites
except the “other medical” category, with inpatient care
having the highest cost. The increased costs with 1.5
MDI SABA doses/day were significant for all sites except
inpatient or outpatient care. For patients using nebulized
and MDI SABA, the difference in cost between patients
using <1.5 SABA doses/day and patients using 1.5 SABA
doses/day was significant in all categories except
outpatient care. IMPACT showed significantly higher
costs for pharmaceuticals with 1.5 nebulized SABA
doses/day and for office visits and pharmaceuticals with
1.5 MDI SABA doses/day. For patients using both nebu-
lized and MDI SABA, significantly higher cost was associ-
ated with 1.5 SABA doses/day in the categories ofinpatient care, outpatient care, office visits, and
pharmaceuticals.
Sensitivity and specificity
The overall sensitivity and specificity for identifying pa-
tients with 2 exacerbations PPY (using the marker of
1.5 SABA doses/day) were 44.3% and 68.0%, respec-
tively, in ORD and 35.7% and 73.6%, respectively, in
IMPACT (Table 4). This suggests that the marker is suc-
cessful at identifying patients at low risk for future ex-
acerbations and costs (specificity), but less so at
accurately predicting risk of exacerbations. Sensitivity
and specificity for the 1.5 doses/day cutoff were exam-
ined within various patient subgroups to determine if the
marker would be applicable across multiple patient types.
Marker performance was similar across various insurance
and age groups, although sensitivity was slightly worse
and specificity slightly improved in the youngest age group
(40e54 years). Among patients using ICS/LABA or LAMA,
sensitivity was higher (and specificity lower) for patients
highly compliant with SABA (MPR 0.8 versus <0.8);
however, the type of concomitant medication (ie, ICS/
LABA or LAMA) did not seem to affect this relationship.
Reducing the analysis period from a year to 90 or 180 days
did not substantially alter sensitivity and specificity, sug-
gesting that assessing SABA use over a shorter time period
does not impact the performance of the marker. Findings
were similar between databases.
Discussion
In this analysis, use of 1.5 SABA doses/day (nebulized or
MDI) by patients with COPD was associated with signifi-
cantly greater risk of exacerbation and significantly higher
health care costs. The robustness of this finding, and its
potential usefulness as a clinical marker, is supported by
the consistency of results between two databases and by
various sensitivity analyses.
Table 2 Medication use during the year posteindex date with corresponding MPR in ORD and IMPACT combined, N Z 66,004.
SABA delivery Nebulized
SABA only
p value
MDI SABA
only
p value
Nebulized þ
MDI SABA
p value
Nebulized SABA only MDI SABA only Nebulized
þ MDI SABA
<1.5 Doses/day
(n Z 10,195)
1.5 Doses/day
(n Z 3347)
<1.5 Doses/day
(n Z 26,924)
1.5 Doses/day
(n Z 10,447)
<1.5 Doses/day
(n Z 5269)
1.5 Doses/day
(n Z 9822)
Rescue medications
SAMA (monotherapy) use
Patients with
any fill
n 2087 924 669 451 887 2154
% 20.47 27.61 2.48 4.32 16.83 21.93 <0.001 <0.001 <0.001
SAMA/SABA combination use
Patients with
any fill
n 4080 1702 5845 4052 2360 5675
% 40.02 50.85 21.71 38.79 44.79 57.78 <0.001 <0.001 <0.001
Systemic corticosteroid use
Patients with
any fill
n 5427 2024 13,400 5050 3918 7589
% 53.23 60.47 49.77 48.34 74.36 77.27 <0.001 0.013 <0.001
Maintenance medications
ICS (monotherapy) use
Patients with
any fill
n 1301 674 2904 1825 890 2222
% 12.76 20.14 10.79 17.47 16.89 22.62 <0.001 <0.001 <0.001
Patients with
MPR  0.8
n 51 126 191 371 40 329
% 6.00 18.83 6.61 20.43 5.39 15.71 <0.001 <0.001 <0.001
MPR (continuous) Mean 0.27 0.45 0.28 0.49 0.24 0.40 <0.001 <0.001 <0.001
SD 0.26 0.31 0.25 0.30 0.23 0.31
ICS/LABA combination use
Patients with
any fill
n 2392 1046 9979 4796 2373 5383
% 23.46 31.25 37.06 45.91 45.04 54.81 <0.001 <0.001 <0.001
Patients with
MPR  0.8
n 379 239 1614 1555 319 1284
% 15.84 22.87 16.17 32.42 13.44 23.85 <0.001 <0.001 <0.001
MPR (continuous) Mean 0.40 0.50 0.41 0.59 0.39 0.51 <0.001 <0.001 <0.001
SD 0.30 0.30 0.30 0.31 0.29 0.31
Methylxanthine use
Patients with
any fill
n 425 201 722 590 301 1017
% 4.17 6.01 2.68 5.65 5.71 10.35 <0.001 <0.001 <0.001
Patients with
MPR  0.8
n 150 86 191 281 86 407
% 41.21 46.24 33.63 53.73 33.59 42.62 0.260 <0.001 0.009
MPR (continuous) Mean 0.59 0.65 0.53 0.71 0.53 0.62 0.082 <0.001 <0.001
SD 0.35 0.34 0.36 0.32 0.36 0.34
Nonnebulized LABA use
Patients with
any fill
n 203 115 725 522 156 488
% 1.99 3.44 2.69 5.00 2.96 4.97 <0.001 <0.001 <0.001
Patients with
MPR  0.8
n 46 37 174 183 27 152
% 22.66 32.17 24.00 35.06 17.31 31.15 0.063 <0.001 <0.001
MPR (continuous) Mean 0.47 0.57 0.48 0.60 0.42 0.54 0.009 <0.001 <0.001
SD 0.32 0.33 0.32 0.31 0.31 0.33
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Figure 3 Distribution of SABA use by number of exacerba-
tions, N Z 56,581 (ORD). One dose of nebulized SABA was
defined as 1 nebulization using 1 vial (2.5 mg albuterol equiv-
alent). One dose of MDI SABA was defined as 2 puffs (1
puffZ 90 mcg albuterol equivalent). CIZ confidence interval;
COPDZ chronic obstructive pulmonary disease; ORDZ Optum
Research Database; SABA Z short-acting inhaled b2-agonist.
1316 A. Sharafkhaneh et al.The ORD and IMPACT databases contained >56,000 and
>9000 patients, respectively, who met inclusion criteria.
Mean patient age (68 years, ORD; 62 years, IMPACT) and
male/female composition (44%/56%, ORD; 45%/55%,
IMPACT) were consistent with epidemiologic studies
describing COPD profiles in Canada and the United States
[2,20]. The statistically significant positive correlation be-
tween frequency of SABA use and exacerbations PPY in ORD
allowed us to determine a clinically meaningful threshold
(ie, marker) of SABA use. Relying on recommendations from
the GOLD Initiative, [19] we identified a level of SABA use
associated with 2 exacerbations per year, an indicator of
increased risk and need for treatment reevaluation.
Determining which patients need reevaluation of main-
tenance therapy is important to clinicians, patients,
payers, and public health officials. Less than half of the
patients evaluated were receiving maintenance therapy.
This important finding is consistent with results from a
recent study showing that 66% and 71% of patients withLess than 1.5
SABA doses 
per day
(64%)
1.5 or more
SABA doses 
per day
(36%)
1.3 1.4 1.5 1.6 1.7 1.8 1.9 2
Number of exacerbations (per patient per year)
Mean with 95% CI
1.36
1.92
p < 0.0001
Figure 4 Mean exacerbations per patient per year using a
cutoff of 1.5 doses of SABA (1 doseZ 1 vial nebulized SABA or 2
puffs MDI SABA) in ORD and IMPACT combined, N Z 66,004.
CI Z confidence interval; IMPACT Z Impact National
Benchmark Database; MDI Z metered-dose inhaler;
ORD Z Optum Research Database; SABA Z short-acting
inhaled b2-agonist.
Table 3 Costs per year (2010 $US) in the year posteindex date for the ORD and IMPACT patient populations by SABA type and
site of care.
ORD IMPACT
<1.5 Doses/day 1.5 Doses/day p Value <1.5 Doses/day 1.5 Doses/day p Value
Nebulized SABA
only
n Z 9306 n Z 3148 n Z 889 n Z 199
COPD-related
total costs (PPY),
mean (SD)
11,686.44
(32,707.21)
21,867.86
(53,910.13)
<0.001 10,577.25
(59,959.88)
16,566.24
(52,766.70)
0.159
Inpatient 9098.25
(31,796.54)
17,525.06
(52,651.21)
<0.001 8641.02
(59,336.42)
13,375.12
(52,238.79)
0.261
Emergency
department
164.42 (773.45) 275.51 (1357.97) <0.001 103.45 (429.68) 119.68 (380.58) 0.596
Outpatient 617.31 (2901.18) 898.03 (3968.39) <0.001 398.72 (2281.05) 408.91 (2740.96) 0.961
Office visit 287.78 (1147.92) 350.69 (1238.97) 0.012 316.41 (383.44) 303.10 (396.55) 0.660
Other medical 957.68 (2110.92) 976.25 (1744.48) 0.625 386.20 (3144.25) 454.43 (1031.83) 0.595
Pharmaceutical 529.06 (935.51) 1782.58 (1832.27) <0.001 702.55 (1090.45) 1859.73 (1787.89) <0.001
MDI SABA only n Z 21,887 n Z 8905 n Z 5037 n Z 1542
COPD-related
total costs (PPY),
mean (SD)
7333.93
(24,853.49)
9216.39
(30,710.31)
<0.001 5094.99
(14,532.00)
5770.90
(12,399.49)
0.073
Inpatient 5230.52
(24,062.74)
5669.04
(29,960.33)
0.219 3303.97
(14,014.26)
2682.79
(11,851.05)
0.085
Emergency
department
88.89 (479.17) 123.79 (657.60) <0.001 77.09 (551.55) 94.59 (561.96) 0.278
Outpatient 633.16 (3074.86) 654.10 (2847.26) 0.568 417.08 (1925.19) 441.93 (1433.95) 0.585
Office visit 302.76 (659.36) 337.36 (729.35) <0.001 278.73 (333.63) 325.31 (354.15) <0.001
Other medical 238.89 (1162.34) 368.11 (1187.97) <0.001 102.98 (636.45) 136.00 (837.16) 0.154
Pharmaceutical 819.66 (1041.91) 2038.81 (1475.96) <0.001 901.21 (1115.54) 2074.52 (1479.51) <0.001
Nebulized D MDI
SABA
n Z 4505 n Z 8830 n Z 764 n Z 992
COPD-related
total costs (PPY),
mean (SD)
11,232.65
(27,005.86)
15,805.73
(35,260.01)
<0.001 7952.04
(18,996.95)
12,534.35
(29,452.12)
<0.001
Inpatient 8166.61
(25,710.64)
10,689.88
(33,188.68)
<0.001 5503.74
(18,246.81)
8258.06
(28,518.52)
0.014
Emergency
department
177.51 (657.46) 265.56 (1084.17) <0.001 198.29 (839.23) 267.28 (1348.75) 0.189
Outpatient 816.41 (4547.45) 899.56 (3408.82) 0.279 401.87 (1292.00) 570.25 (1608.50) 0.015
Office visit 376.22 (490.62) 482.47 (755.71) <0.001 349.78 (549.49) 477.91 (1376.11) 0.008
Other medical 693.04 (1425.61) 1065.84 (6605.16) <0.001 386.67 (1844.45) 466.44 (1663.59) 0.349
Pharmaceutical 972.16 (1121.91) 2359.24 (1826.77) <0.001 1089.97 (1191.29) 2460.16 (1851.53) <0.001
COPDZ chronic obstructive pulmonary disease; IMPACTZ Impact National Benchmark Database; MDIZmetered-dose inhaler; ORDZ
Optum Research Database; PPY Z per patient year; SABA Z short-acting inhaled b2-agonist; SD Z standard deviation.
Rule of 3e2 for COPD 1317COPD enrolled in several US commercial health plans and
Medicare, respectively, did not receive any maintenance
therapy [21]. Additionally, in our analysis, adherence to
maintenance therapy (assessed by MPR) was generally poor.
Relatively few patients had an MPR  0.80, which has been
suggested as a reasonable long-term adherence threshold
providing greater efficacy for inhaled drugs [22]. Patients
using more doses of SABA (ie, those at greater risk of ex-
acerbations) were more often receiving combination ther-
apy and adhering to its use. However, sensitivity analyses
indicated that performance characteristics for the 1.5 SABAdoses/day threshold, which identified an increased risk of
exacerbations, was not affected by concomitant medica-
tion use.
A major challenge for clinicians is deciding when to
escalate therapy. Spirometry, while helpful in diagnosis
and staging, continues to be underutilized, and even when
it is performed, it does not help to determine disease
stability. Questionnaires such as the COPD Assessment
Test may be helpful but are underutilized [23]. Hence,
there is a clear need for a simple, easy-to-use clinical
marker to better guide patient care. For chronic asthma,
Table 4 SABA marker sensitivity and specificity.
ORD (N Z 56,581) IMPACT
(N Z 9423)
Positive
test
counta
(n)
Positive test
probabilityb
(%)
Sensitivityc
(%)
Specificityd
(%)
Positive
test
counta
(n)
Positive test
probabilityb
(%)
Sensitivityc
(%)
Specificityd
(%)
Overall 20,883 36.91 44.31 67.97 2733 29.00 35.74 73.62
Commercially
insured
10,277 34.85 43.52 70.08 2040 27.94 34.75 74.68
Medicare
Advantage
10,606 39.15 45.04 65.38 693 32.66 39.05 69.93
Reference window of SABA use
First 90 d
post-index
21,075 37.25 42.68 66.33 2912 30.90 36.16 71.14
First 180 d
post-index
22,192 39.22 45.50 64.91 2985 31.68 36.92 70.36
Concomitant medications
ICS/LABA
MPR < 0.8 7131 40.89 47.97 65.21 1015 32.32 39.48 71.39
MPR  0.8 2657 59.75 66.72 45.21 421 44.64 54.91 59.58
LAMA (tiotropium)
MPR < 0.8 4800 41.31 48.01 65.76 631 33.30 39.55 70.52
MPR  0.8 2615 54.60 61.27 50.58 397 43.58 53.56 61.20
Age category (y)
4054 2414 30.18 39.49 74.35 552 24.75 31.27 77.30
5564 5155 36.68 45.35 68.66 1025 28.50 36.81 74.82
6574 6720 39.22 46.22 65.80 642 32.10 36.38 69.69
75þ 6594 37.91 43.42 66.11 514 32.19 37.63 70.22
ICSZ inhaled corticosteroid; IMPACTZ Impact National Benchmark Database; LABAZ long-acting inhaled b2-agonist; LAMAZ long-
acting inhaled muscarinic antagonist; MPR Z medication possession ratio; ORD Z Optum Research Database; SABA Z short-acting
inhaled b2-agonist.
a Number of patients with daily use above marker level.
b Percentage of patients with daily use above marker level.
c Percentage of patients with 2 exacerbations that have daily use above marker level.
d Percentage of patients with <2 exacerbations that have daily use below marker level.
1318 A. Sharafkhaneh et al.the Rules of Two were developed to assist patients and
physicians with recognizing when to reevaluate mainte-
nance therapy [24]. Similarly, the marker in our study
serves as a proactive indicator for treatment
reevaluation.
The large health care burden imposed by COPD is
amplified by costs associated with poor disease control and
exacerbations [25e27]. Our analysis revealed significantly
higher health care costs in patients using 1.5 SABA doses/
day. Overall, patients using nebulized (versus MDI) SABA
had significantly higher health care costs, which may reflect
higher disease severity in these patients. In ORD, health
care costs were 87% higher for patients using 1.5 (versus
<1.5) nebulized (only) SABA doses/day; health care costs
were 26% higher for patients using 1.5 (versus <1.5) MDI
(only) SABA doses/day.
There are limitations to this study. Information available
in the databases was not sufficient to enable COPD severity
categorization using GOLD-recommended approaches.
However, the percentage of patients with 2 exacerbations
in the assessment year, which varied from about 21% to 60%
in the various subgroups included in the analysis, suggeststhat higher severity of COPD was common [28]. The nature
of using pharmacy refills as an index of medication use
limits time period analysis. However, sensitivity analyses
showed that the 1.5 SABA doses/day threshold for identi-
fying an increased risk of exacerbations worked well using
follow-up periods shorter than 1 year, including periods as
short as 90 days. In clinical practice, a 3-month period can
be used easily during regular outpatient evaluations. This
should reassure clinicians that using this threshold will be of
clinical value, similar to the Rules of Two, which are based
on intensity of rescue inhaler use [13,24]. The marker has
low sensitivity (but high specificity) in predicting future
exacerbations. The sensitivity of the SABA marker could
potentially be improved by taking into account other fac-
tors (eg, smoking and comorbidities), which also predict
uncontrolled asthma [29]. Despite the lower than optimal
sensitivity, the marker did predict future exacerbations
among approximately 35% of those with SABA use above the
1.5 doses/day level. These represent potentially avoidable
exacerbations if the patient therapy plan were
reevaluated. The proposed use of the marker is to signal to
physicians that reevaluation of current therapy may be
Rule of 3e2 for COPD 1319warranted; the consequence of the “intervention” for pa-
tients who were ultimately not at high risk for exacerba-
tions (the “false positives”) is minimal and may still lead to
improved COPD management. Regarding potential limita-
tions associated with the methodology, previously validated
ICD-9-CM codes were used to identify exacerbations [30],
although occasional coding errors are possible. Also, it is
unknown whether our results would be similar in an unin-
sured population. To test any impact of the observational
nature of the data on study results, ORD results were vali-
dated with IMPACT.
Conclusion
Using a representative sample of the insured population of
the United States, we developed a new tool that identifies a
high-risk COPD population based on rescue medication use.
We hope such a tool may be used to more effectively
manage COPD and close the gap between clinical guidelines
and clinical practice. Patients with COPD regularly using
1.5 SABA doses/day were at increased risk of exacerba-
tions in our analysis and could benefit from treatment
reevaluation. We recommend the “Rule of 3e2” (SABA use
3 times in 2 days) to be considered as an easily remem-
bered and easily implemented tool to quickly evaluate the
need for treatment reevaluation.
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